OncoMatch/Clinical Trials/NCT04522544
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
Is NCT04522544 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Tremelimumab and Durvalumab for hepatocellular carcinoma non-resectable.
Treatment: Tremelimumab · Durvalumab — A Phase II study of immunotherapy with Durvalumab (MEDI4736) and Tremelimumab in combination with Y-90 SIRT for intermediate stage HCC
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer therapy
No prior systemic anti-cancer therapy
Cannot have received: radiotherapy
Exception: administered < 4 weeks prior to study entry
radiotherapy administered < 4 weeks prior to study entry
Cannot have received: endocrine therapy
endocrine- or immunotherapy or use of other investigational agents
Cannot have received: immunotherapy
endocrine- or immunotherapy or use of other investigational agents
Cannot have received: investigational agent
Exception: used within 4 weeks prior to the first dose of study treatment
has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
Cannot have received: locoregional therapy
Exception: ongoing or completed < 4 weeks prior to the baseline scan
Locoregional therapies ongoing or completed < 4 weeks prior to the baseline scan
Lab requirements
Blood counts
Hemoglobin ≥ 9.0 g/dL, ANC ≥1.5 (or 1.0) x (> 1500 per mm^3), platelets ≥100 (or 75) x 10^9/L (>75,000 per mm^3)
Kidney function
Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine clearance CL>40 mL/min by Cockcroft-Gault formula or by 24-hour urine collection
Liver function
Child-Pugh A; Serum bilirubin ≤1.5 x institutional ULN; AST (SGOT), ALT (SGPT) ≤ 2.5 x institutional ULN unless liver metastases are present, in which case ≤5x ULN; INR ≤ 1.25; Albumin ≥ 31 g/dL
Adequate blood count, liver-enzymes, and renal function: Hemoglobin ≥ 9.0 g/dL, ANC ≥1.5 (or 1.0) x (> 1500 per mm^3), platelets ≥100 (or 75) x 10^9/L (>75,000 per mm^3); Serum bilirubin ≤1.5 x institutional ULN; AST (SGOT), ALT (SGPT) ≤ 2.5 x institutional ULN unless liver metastases are present, in which case ≤5x ULN; INR ≤ 1.25. Albumin ≥ 31 g/dL. Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine clearance CL>40 mL/min by Cockcroft-Gault formula or by 24-hour urine collection
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify